VistaGen Therapeutics, Inc. (VTGN)
Market Cap | 30.06M |
Revenue (ttm) | -363,900 |
Net Income (ttm) | -63.71M |
Shares Out | 232.67M |
EPS (ttm) | -0.32 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,317,372 |
Open | 0.140 |
Previous Close | 0.138 |
Day's Range | 0.125 - 0.140 |
52-Week Range | 0.080 - 1.790 |
Beta | 1.10 |
Analysts | Sell |
Price Target | 0.20 (+54.8%) |
Earnings Date | Feb 7, 2023 |
About VTGN
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder... [Read more]
Financial Performance
In 2022, VTGN's revenue was $1.11 million, an increase of 1.78% compared to the previous year's $1.09 million. Losses were -$48.71 million, 15.1% more than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VTGN stock is "Sell." The 12-month stock price forecast is $0.2, which is an increase of 54.80% from the latest price.
News

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individual...

Vistagen to Present at Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th...

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen to Acquire Pherin Pharmaceuticals
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen Announces Publication in Cells Demonstrating AV-101's Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,...

What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety...

Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
SOUTH SAN FRANCISCO, Calif.

Vistagen to Present at Stifel 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.

Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
SOUTH SAN FRANCISCO, Calif.

Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
SOUTH SAN FRANCISCO, Calif.

Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the ...

Vistagen to Participate at Cantor Neurology & Psychiatry Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals li...